trial

Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

NCTId NCT06036108
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 59 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2025-03-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
59 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2023-10-03
Primary completion
2025-03-18
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Takehisa MatsumaruStudy Director

Sites

1 total
Saga, Japan

Facts & assertions

4 sourced
Enrollment
59
Phase
PHASE1
Primary Completion Date
2025-03-18
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Takehisa Matsumaru
person